$42.35▲ 2.06 (5.11%)
Real-time prices · US MarketsQ·Score
Hold
6.1 / 10
High-quality business with 61% return on equity and 33% profit margins.
revenue declining 8% year-over-year.
Quality
9
Health
5.3
Growth
3.4
Valuation
6.6
Sentiment
5
Analyst Target
$46.68
▲ +10.2% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
11.7×
price-to-earnings
Forward P/E
12.3×
next 12 months est.
Market Cap
$187.8B
market capitalization
Div Yield
4.47%
dividend yield
Profit Margin
33.1%
net profit margin
Gross Margin
82.4%
revenue minus COGS
ROE
60.7%
return on equity
Beta
0.27
vs S&P 500
Price / Book
—
P/B ratio
52-Week Range
$35 — $81
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
Is NVO a good stock to buy right now?
Based on our Q·Score of 6.1/10, Novo Nordisk A/S is rated "Hold". High-quality business with 61% return on equity and 33% profit margins. Main risk to consider: revenue declining 8% year-over-year. This analysis is based on fundamentals, analyst consensus, and valuation data, and should not be considered financial advice.
What is the analyst price target for NVO?
The consensus price target for NVO is $46.68, based on the recommendations of 12 Wall Street analysts. This implies 10.2% upside from the current price of $42.35.
Is NVO overvalued or undervalued?
Novo Nordisk A/S (NVO) appears fairly valued at current levels relative to analyst targets and sector peers. It trades at a 12.3× forward P/E ratio. Analysts see 10% upside to their $46.68 consensus target.
When does Novo Nordisk A/S report its next earnings?
Novo Nordisk A/S is scheduled to report earnings in 6 days, on May 6, 2026.
What is Novo Nordisk A/S's profit margin?
Novo Nordisk A/S has a net profit margin of 33.1%, which is considered high and reflects strong pricing power. Its gross margin stands at 82.4%, indicating a high-margin business model.
What is NVO's dividend yield?
Novo Nordisk A/S currently offers a dividend yield of 4.47%, which provides a solid income stream for dividend-focused investors. Dividend yields can change based on price movements and company payout decisions.
Is Novo Nordisk A/S's revenue growing?
Novo Nordisk A/S is reporting revenue declining 7.6% year-over-year. However, earnings declined 4.7%, which warrants monitoring.
How much debt does Novo Nordisk A/S have?
Novo Nordisk A/S has a debt-to-equity ratio of 0.67×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 0.80×, suggesting it should be monitored for near-term liquidity.